Cohance Lifesciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Vohra will succeed Vivek Sharma, who is stepping down as executive chairman for personal reasons. Sharma will continue with Cohance as an advisor for the next nine months to ensure a smooth transition.

Vohra is one of the most accomplished leaders in the pharmaceutical industry. Over a career spanning more than three decades, he has led large, complex, global businesses through periods of strategic transformation while maintaining an unwavering focus on customers, quality and operational excellence. Most recently, as CEO and managing director of Cipla, Vohra led the company?s transformation over the last decade to build a diversified global pharmaceutical enterprise. Having worked in and transformed two very large and respected Pharma companies in India, Vohra brings an owner-mindset and vast experience in business to the Cohance platform.

The company said the appointment reflects a deliberate, strategic decision taken by the board, to bring in a leader whose profile is specifically suited to the demands of Cohance?s transformation and its next phase of growth.

Commenting on appointment, Umang Vohra said, ?I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance?s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike.

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. It is a technology-driven, integrated CDMO platform offering development and manufacturing solutions across complex APIs, performance materials, agrochemicals, ADCs, oligonucleotides and advanced chemistries for global pharmaceutical and life sciences customers.

The company?s consolidated net profit dropped 76% to Rs 36.72 crore on 19.5% decline in revenue from operations to Rs 544.55 crore in Q3 FY26 over Q3 FY25.

The board of Cohance Lifesciences at its meeting held on 27 April 2026 has approved the following:

Noted the resignation of Vivek Sharma (DIN 08559495), as Executive Chairman and director of the Company with effect from 30 April 2026.

Approved the appointment of Umang Vohra as Additional Director, designated as Chairman, and Group Chief Executive Officer with effect from 01 May 2026 and 20 May 2026 respectively.

Net profit of Cohance Lifesciences declined 76.01% to Rs 36.72 crore in the quarter ended December 2025 as against Rs 153.07 crore during the previous quarter ended December 2024. Sales declined 19.47% to Rs 544.55 crore in the quarter ended December 2025 as against Rs 676.23 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

 Cohance Lifesciences announced that the US FDA conducted an inspection at the Company's Finished Dosage Formulations manufacturing facility (FDF Unit-I) located at Nacharam, Hyderabad, from 04 August 2025 to 12 August 2025. Following the inspection, a Form FDA-483 containing six observations was issued by the US FDA. Based on these observations, the USFDA classified the facility as ?Official Action Indicated (OAI)? and subsequently issued a Warning Letter for the said facility.

The Company is required to respond to the Warning Letter within the stipulated timelines prescribed by the US FDA and continues to engage with the regulator thereafter.

The US revenues from this facility contributed less than 2% of consolidated revenues in FY25, with related EBITDA contribution below 1%.

Powered by Capital Market - Live News